Investors warm up to the idea of Pfizer snapping up GSK

Some analysts may be slamming a potential Pfizer ($PFE) buyout of GlaxoSmithKline ($GSK), but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months. Much of that interest has to do with chatter about a Pfizer takeover, traders told the news service. But it's not the only factor. More from FiercePharma